NEW YORK (GenomeWeb News) — Exosome Diagnostics said today that it has entered into a collaboration agreement with Eli Lilly for biomarker discovery and validation using Exosome's EXO50 nucleic acid extraction kit.

Under the agreement, the financial terms of which were not disclosed, Lilly will gain early access to Exosome's technology to help it identify key gene mutations and expression levels in blood that may be correlated with drug response and disease recurrence.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.